Over the recent years, incretin-based medications have exhibited remarkable achievements in the treatment of type 2 diabetes and obesity. Particularly noteworthy are their significant effects, with semaglutide and tirzepatide showcasing impressive weight loss of 15% and 20% in non-diabetic individuals, respectively. Moreover, these medications have revealed discernible benefits in cardiovascular and non-alcoholic fatty liver diseases. This session will delve into the most recent insights on various multi-receptor agonists, exploring their diverse interactions with gastrointestinal hormones.

In this session, titled 'New targets for lipid-lowering therapies,' three esteemed speakers will share their insights. First, Prof. Sung Hee Choi will enlighten us on the latest findings regarding lipoprotein(a) and its therapy. Next, Prof. Sang Hak Lee will address the intriguing subject of angiopoietin-like protein 3, which has recently garnered significant attention. Finally, Prof. In-Kyung Jeong will provide a comprehensive overview of the rekindled interest in triglycerides.

Fat cells exhibit variations in color, size, and location, each playing distinct roles in the body. Brown and beige fat are associated with metabolic benefits in contrast to white fat. While larger adipocytes are often considered as metabolically detrimental, inadequate growth of fat size can lead to harmful ectopic fat accumulation. This session explores the mechanisms that govern the color and size of fat cells, discussing both benefits and harms. Additionally, it will address the diverse characteristics of fat based on deposit location, drawing insights from single-cell analysis data.

The rapid development of artificial intelligence has significantly impacted the study of metabolic diseases. This session will offer an informative opportunity to glean insights from leading researchers in three key areas that have experienced noteworthy advancements with artificial intelligence in recent years within the realm of cardio-metabolic diseases: fully automated insulin delivery without human intervention, precision medicine and big data research, and digital therapeutics for obesity.